FIG. 4.

Effect of ER ligands on expression of chromatin remodeling, coactivator, and cell cycle proteins. (A) Treatment with estrogen agonists and antagonists does not alter chromatin remodeling or coactivator protein levels. MCF-7 cells were pretreated with 10 nM E2 (lanes 3 and 4), 10 nM DES (lanes 5 and 6), or 100 nM raloxifene (lanes 7 and 8). Forty-eight hours posttreatment, cells were untreated (lane 1) or treated with 1 nM DEX (lane 2) or ER ligands and DEX (lanes 4, 6, and 8) for 12 h. Western blotting analysis was done with antibodies specific for BRG1, brm, SRC1, and SRC3. (B) Estrogen agonists inhibit glucocorticoid induction of p21 protein. Cells were treated as described in the legend for panel A. Western blotting analysis was performed with antibodies specific for p21, p27, and cyclin D1. E, E2; D, DES; R, raloxifene.